Marker Therapeutics, Inc.
MRKR
$1.60
$0.031.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -84.50% | 16.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.50% | 16.92% | |||
| Cost of Revenue | -38.35% | 46.53% | |||
| Gross Profit | 1.70% | -83.43% | |||
| SG&A Expenses | 33.32% | 20.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.31% | 41.32% | |||
| Operating Income | -7.62% | -60.90% | |||
| Income Before Tax | -17.39% | -64.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.86% | -66.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.86% | -66.26% | |||
| EBIT | -7.62% | -60.90% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 4.28% | -61.65% | |||
| Normalized Basic EPS | 12.87% | -59.49% | |||
| EPS Diluted | 4.28% | -60.85% | |||
| Normalized Diluted EPS | 12.87% | -59.49% | |||
| Average Basic Shares Outstanding | 21.01% | 2.85% | |||
| Average Diluted Shares Outstanding | 21.01% | 2.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||